Compile Data Set for Download or QSAR
maximum 50k data
Found 1917 with Last Name = 'youngman' and Initial = 'm'
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364562(N-((4bR,6S,8aS,9R)-11- (cyclopropylmethyl)- 3-hydr...)
Affinity DataKi:  0.0190nMAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364547((4bR,6S,8aS,9R)-N-benzyl-11- (cyclopropylmethyl)-3...)
Affinity DataKi:  0.0260nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364552(N-((4bR,6S,8aS,9R)-11- (cyclopropylmethyl)- 3-meth...)
Affinity DataKi:  0.0320nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364548((4bR,6S,8aS,9R)-N-(cyclohexylmethyl)-11- (cyclopro...)
Affinity DataKi:  0.0520nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364561(N-((4bR,6S,8aS,9R)-11- (cyclopropylmethyl)- 3-hydr...)
Affinity DataKi:  0.0560nMAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364559(4-Chloro-N-((4bR,6S,8aS,9R)-11- (cyclopropylmethyl...)
Affinity DataKi:  0.0570nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364561(N-((4bR,6S,8aS,9R)-11- (cyclopropylmethyl)- 3-hydr...)
Affinity DataKi:  0.0590nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364562(N-((4bR,6S,8aS,9R)-11- (cyclopropylmethyl)- 3-hydr...)
Affinity DataKi:  0.0620nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364549((4bR,6S,8aS,9R)-6-amino-11- (cyclopropylmethyl)-5,...)
Affinity DataKi:  0.0960nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM151177(BDBM151178 | US8987287, 7)
Affinity DataKi:  0.200nM ΔG°:  -55.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM151177(BDBM151178 | US8987287, 7)
Affinity DataKi:  0.230nM ΔG°:  -55.0kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364559(4-Chloro-N-((4bR,6S,8aS,9R)-11- (cyclopropylmethyl...)
Affinity DataKi:  0.290nMAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50147083(1-(4-tert-Butyl-benzyl)-3-isoquinolin-5-yl-urea | ...)
Affinity DataKi:  0.300nMAssay Description:Binding affinity towards human vanilloid receptor subtype 1 expressed in HEK293 cell membrane using [3H]-RTX as radioligand.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364557(N-((4bR,6S,8aS,9R)-11- (cyclopropylmethyl)- 3-meth...)
Affinity DataKi:  0.300nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM151184(US8987287, 63)
Affinity DataKi:  0.300nM ΔG°:  -54.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364556(N-((4bR,6S,8aS,9R)-11- (cyclopropylmethyl)- 3-meth...)
Affinity DataKi:  0.330nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM151183(US8987287, 49)
Affinity DataKi:  0.470nM ΔG°:  -53.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM151173(US8987287, 3)
Affinity DataKi:  0.600nM ΔG°:  -52.6kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364555(N-((4bR,6S,8aS,9R)-11- (cyclopropylmethyl)- 3-meth...)
Affinity DataKi:  0.600nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364558(N-((4bR,6S,8aS,9R)-11- (cyclopropylmethyl)- 3-meth...)
Affinity DataKi:  0.660nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364549((4bR,6S,8aS,9R)-6-amino-11- (cyclopropylmethyl)-5,...)
Affinity DataKi:  0.790nMAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50223336(1-(1-(cyclopropylmethyl)-6-fluoro-1,2,3,4-tetrahyd...)
Affinity DataKi:  0.800nMAssay Description:Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50147069(1-(4-Chloro-3-trifluoromethyl-benzyl)-3-isoquinoli...)
Affinity DataKi:  0.800nMAssay Description:Binding affinity towards human vanilloid receptor subtype 1 expressed in HEK293 cell membrane using [3H]-RTX as radioligand.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM151184(US8987287, 63)
Affinity DataKi:  0.860nM ΔG°:  -56.1kJ/molepH: 7.4 T: 2°CAssay Description:mu-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Per...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364548((4bR,6S,8aS,9R)-N-(cyclohexylmethyl)-11- (cyclopro...)
Affinity DataKi:  0.930nMAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM151175(US8987287, 5)
Affinity DataKi:  0.940nM ΔG°:  -51.5kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364546((4bR,6S,8aS,9R)-11-(cyclopropylmethyl)- 3,6-dihydr...)
Affinity DataKi:  0.950nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50223313(1-(1-(4-bromobenzyl)-6-methoxy-1,2,3,4-tetrahydron...)
Affinity DataKi:  1nMAssay Description:Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50223314(1-(1-(4-(trifluoromethyl)benzyl)-6-fluoro-1,2,3,4-...)
Affinity DataKi:  1nMAssay Description:Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50147080(3-(4-tert-Butyl-phenyl)-N-isoquinolin-5-yl-acrylam...)
Affinity DataKi:  1.20nMAssay Description:Antagonistic activity towards human vanilloid receptor subtype 1 expressed in HEK293 cell membrane, as inhibition of agonist-induced intracellular [C...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50147067(1-[2-(4-tert-Butyl-phenyl)-ethyl]-3-isoquinolin-5-...)
Affinity DataKi:  1.30nMAssay Description:Binding affinity towards human vanilloid receptor subtype 1 expressed in HEK293 cell membrane using [3H]-RTX as radioligand.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50147063(1-Isoquinolin-5-yl-3-(4-trifluoromethoxy-benzyl)-u...)
Affinity DataKi:  1.30nMAssay Description:Binding affinity towards human vanilloid receptor subtype 1 expressed in HEK293 cell membrane using [3H]-RTX as radioligand.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50147077(1-(3,5-Bis-trifluoromethyl-phenyl)-3-isoquinolin-5...)
Affinity DataKi:  1.40nMAssay Description:Antagonistic activity towards human vanilloid receptor subtype 1 expressed in HEK293 cell membrane, as inhibition of agonist-induced intracellular [C...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364553(N-((4bR,6S,8aS,9R)-11- (cyclopropylmethyl)- 3-meth...)
Affinity DataKi:  1.58nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50223328(1-(1-benzyl-5-chloro-1,2,3,4-tetrahydronaphthalen-...)
Affinity DataKi:  2nMAssay Description:Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50223330(1-(1-allyl-6-fluoro-1,2,3,4-tetrahydronaphthalen-2...)
Affinity DataKi:  2nMAssay Description:Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50223331(1-(1-benzyl-6-bromo-1,2,3,4-tetrahydronaphthalen-2...)
Affinity DataKi:  2nMAssay Description:Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50223338(1-(1-(4-(trifluoromethyl)benzyl)-6-methoxy-1,2,3,4...)
Affinity DataKi:  2nMAssay Description:Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50223321(1-(1-(3-chlorobenzyl)-6-methoxy-1,2,3,4-tetrahydro...)
Affinity DataKi:  2nMAssay Description:Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM151183(US8987287, 49)
Affinity DataKi:  2.28nM ΔG°:  -53.5kJ/molepH: 7.4 T: 2°CAssay Description:mu-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Per...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364560(1-Chlorophenyl-3-((4bR,6S,8aS,9R)-11- (cyclopropyl...)
Affinity DataKi:  2.56nMAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recomb...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50223333(1-(1-benzyl-6-methoxy-1,2,3,4-tetrahydronaphthalen...)
Affinity DataKi:  3nMAssay Description:Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM364560(1-Chlorophenyl-3-((4bR,6S,8aS,9R)-11- (cyclopropyl...)
Affinity DataKi:  3.51nMAssay Description:Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Purdue Pharma

US Patent
LigandPNGBDBM151175(US8987287, 5)
Affinity DataKi:  3.55nM ΔG°:  -52.3kJ/molepH: 7.4 T: 2°CAssay Description:mu-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Per...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetB2 bradykinin receptor(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50126226(3-[5-(4-Cyano-benzoyl)-1-methyl-1H-pyrrol-2-yl]-N-...)
Affinity DataKi:  4nMAssay Description:Binding affinity towards human bradykinin receptor B2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50223335(1-(1-benzyl-1,2,3,4-tetrahydronaphthalen-2-yl)-3-(...)
Affinity DataKi:  4nMAssay Description:Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50223340(1-(1-benzyl-6-fluoro-1,2,3,4-tetrahydronaphthalen-...)
Affinity DataKi:  4nMAssay Description:Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50223323(1-(isoquinolin-5-yl)-3-(3-phenyl-2-(4-(trifluorome...)
Affinity DataKi:  4nMAssay Description:Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50223315(1-(6-fluoro-1-(thiophen-2-ylmethyl)-1,2,3,4-tetrah...)
Affinity DataKi:  4nMAssay Description:Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50147060(3-[4-(1,1-Dimethyl-propyl)-phenyl]-N-isoquinolin-5...)
Affinity DataKi:  4nMAssay Description:Binding affinity towards human vanilloid receptor subtype 1 expressed in HEK293 cell membrane using [3H]-RTX as radioligand.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 1917 total ) | Next | Last >>
Jump to: